Robert Peter Kadlec - Oct 30, 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: Director
Signature: /s/Christine Klaskin, as Attorney-in-Fact
Stock symbol: INKT
Transactions as of: Oct 30, 2024
Transactions value $: $8,969
Form type: 4
Date filed: 12/9/2024, 04:10 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INKT	Common Stock	Award	$8.97K	+12.3K		$0.73	12.3K	Dec 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INKT	Stock Option	Award	$0	+41.7K		$0.00	41.7K	Oct 30, 2024	Common Stock	41.7K	$0.72	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on October 30, 2024 and will vest in three equal annual installments on each of October 30, 2025, 2026 and 2027 (provided Dr. Kadlec maintains a service relationship with the company through each such vesting date).
F2	Dr. Kadlec was granted restricted stock unites ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.